Search

Xenon Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

63.15 1.32

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

60.96

Max

62.73

Schlüsselkennzahlen

By Trading Economics

Einkommen

-8.4M

-111M

EPS

-1.11

Angestellte

358

EBITDA

420K

-111M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+25.08% upside

Dividenden

By Acuity

Nächstes Ergebnis

2. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

190M

6.2B

Vorheriger Eröffnungskurs

61.83

Vorheriger Schlusskurs

63.15

Nachrichtenstimmung

By Acuity

60%

40%

287 / 340 Ranking in Healthcare

Xenon Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Aug. 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is trading higher in after-market hours, despite no specific news to explain the move. The stock remains below its 20-day moving average.

15. Aug. 2026, 00:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, though no specific news was identified to explain the movement.

14. Aug. 2026, 23:01 UTC

Xenon Pharmaceuticals shares are higher in after-market hours, reflecting a modest gain since Friday's close. The stock remains below its 20-day moving average.

13. Aug. 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are declining, trading below their 20-day moving average amid broader market support, despite rising initial jobless claims.

12. Aug. 2026, 22:51 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, reflecting notable volatility and fluctuations since Wednesday's close within the one-month trading range.

11. Aug. 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and subdued trading activity.

10. Aug. 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite earlier pulling back from a session high. No specific news was identified for the movement.

7. Aug. 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares are lower as RBC cuts the price target to $81.00 and the company reports a larger-than-expected Q2 loss of $110.7 million.

6. Aug. 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. shares are lower today, retracing earlier gains. The stock is trading near the lower end of its one-month range.

5. Aug. 2026, 23:41 UTC

Xenon Pharmaceuticals Inc. shares are higher in after-market hours amid notable volatility, though no specific news was identified to explain the movement.

4. Aug. 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are trading lower during after-market hours, breaking a recent trend of higher daily closes since Tuesday.

3. Aug. 2026, 19:46 UTC

News

Xenon Pharmaceuticals announced equity inducement grants totaling 32,758 share options and 19,013 RSUs. Shares are lower during Monday's session, near the one-month range's low.

31. Juli 2026, 23:01 UTC

News

Xenon Pharmaceuticals shares are lower in after-market hours following the announcement of inducement grants for eleven new non-officer employees.

30. Juli 2026, 13:36 UTC

Xenon Pharmaceuticals Inc shares are higher in pre-market trading, reflecting a broader market recovery despite rising treasury yields and geopolitical tensions.

29. Juli 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are little changed after-market, continuing a trend of three consecutive lower daily finishes amid a broader decline in U.S. equities.

28. Juli 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are lower today, pulling back from earlier gains amid notable volatility and no specific news to explain the movement.

27. Juli 2026, 16:06 UTC

Xenon Pharmaceuticals Inc shares are lower today amid a broader market decline linked to falling crude oil prices and eased geopolitical tensions.

24. Juli 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting positive momentum since Friday's close, despite no specific news identified.

23. Juli 2026, 23:51 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the decline.

22. Juli 2026, 23:11 UTC

Xenon Pharmaceuticals Inc shares declined in after-market trading amid broader market volatility, influenced by geopolitical tensions and rising crude oil prices.

21. Juli 2026, 19:36 UTC

Xenon Pharmaceuticals shares are higher, supported by overall market strength and advances in biotechnology stocks, despite no specific company news identified.

20. Juli 2026, 22:02 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, following notable volatility and no specific news identified. The stock remains above its 20-day moving average.

Peer-Vergleich

Kursveränderung

Xenon Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

25.08% Vorteil

12-Monats-Prognose

Durchschnitt 78 USD  25.08%

Hoch 90 USD

Tief 63 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Xenon Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

12

Buy

0

Halten

0

Sell

Stimmung

By Acuity

287 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat